Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025383 | 0.92 | SLC6A9 (0.85) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4937951 | 0.88 | SLC6A9 (0.78) | SLC6A9GPR55KCNH2 | |
| SCHEMBL8259226 | 0.88 | SLC6A9 (0.85) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4427067 | 0.88 | SLC6A9 (0.86) | SLC6A9GPR55 | |
| SCHEMBL4435029 | 0.87 | SLC6A9 (0.78) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4948286 | 0.87 | SLC6A9 (0.79) | SLC6A9GPR55 | |
| SCHEMBL4424389 | 0.87 | SLC6A9 (0.78) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4940865 | 0.87 | SLC6A9 (0.77) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4435110 | 0.86 | SLC6A9 (0.76) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4434079 | 0.86 | SLC6A9 (0.90) | SLC6A9GPR55KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021243093-A1 | METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FORM VIRAL INFECTIONS | IMMUNOFLEX THERAPEUTICS INC. (CA) | 2021-12-02 | — | — | WO | disclosed |
| US-20210369661-A1 | METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FROM VIRAL INFECTIONS | IMMUNOFLEX THERAPEUTICS INC. (CA) | 2021-12-02 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | SLC6A9 9/4885GPR55 485/4885KCNH2 562/4885 |
| US-20210369661-A1 | METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FROM VIRAL INFECTIONS | IFNG, CD4, MAVS | SLC6A9 4835/4885GPR55 2713/4885KCNH2 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.